Sorrento Therapeutics Inc - ESG Rating & Company Profile powered by AI
Alternative companies in the rating industry group for Sorrento Therapeutics Inc are shownin the table. If you are employed by Sorrento Therapeutics Inc and you wish to licence your ESG rating, please contact us. This analysis of Sorrento Therapeutics Inc uses data points from across the internet as well as from public filings by Sorrento Therapeutics Inc.
Sorrento Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.1; made up of an environmental score of 1.3, social score of 1.1 and governance score of 4.0.
2.1
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1551 | Voyager Life PLC | 2.2 | Medium |
1551 | Source Natural Foods and Herbal Supplements Ltd | 2.2 | Medium |
1571 | Sorrento Therapeutics Inc | 2.1 | Medium |
1571 | Cerevel Therapeutics Holdings Inc | 2.1 | Medium |
1571 | Charlotte's Web Holdings Inc | 2.1 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Sorrento Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Sorrento Therapeutics Inc disclose current and historical energy intensity?
Does Sorrento Therapeutics Inc report the average age of the workforce?
Does Sorrento Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does Sorrento Therapeutics Inc disclose its ethnicity pay gap?
Does Sorrento Therapeutics Inc disclose cybersecurity risks?
Does Sorrento Therapeutics Inc offer flexible work?
Does Sorrento Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Sorrento Therapeutics Inc disclose the number of employees in R&D functions?
Does Sorrento Therapeutics Inc conduct supply chain audits?
Does Sorrento Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Sorrento Therapeutics Inc conduct 360 degree staff reviews?
Does Sorrento Therapeutics Inc disclose the individual responsible for D&I?
Does Sorrento Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Sorrento Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does Sorrento Therapeutics Inc disclose water use targets?
Does Sorrento Therapeutics Inc have careers partnerships with academic institutions?
Did Sorrento Therapeutics Inc have a product recall in the last two years?
Does Sorrento Therapeutics Inc disclose incidents of discrimination?
Does Sorrento Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Sorrento Therapeutics Inc issued a profit warning in the past 24 months?
Does Sorrento Therapeutics Inc disclose parental leave metrics?
Does Sorrento Therapeutics Inc disclose climate scenario or pathway analysis?
Does Sorrento Therapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Sorrento Therapeutics Inc disclose the pay ratio of women to men?
Does Sorrento Therapeutics Inc support suppliers with sustainability related research and development?
Does Sorrento Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Sorrento Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Sorrento Therapeutics Inc involved in embryonic stem cell research?
Does Sorrento Therapeutics Inc disclose GHG and Air Emissions intensity?
Does Sorrento Therapeutics Inc disclose its waste policy?
Does Sorrento Therapeutics Inc report according to TCFD requirements?
Does Sorrento Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Sorrento Therapeutics Inc disclose energy use targets?
Does Sorrento Therapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Sorrento Therapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Sorrento Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patients with melanoma; and Karolinska Institutet. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.